Indivior PLC (INDV)

Market Cap	2.84B
Revenue (ttm)	1.17B
Net Income (ttm)	53.00M
Shares Out	124.77M
EPS (ttm)	0.42
PE Ratio	54.72
Forward PE	14.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,038,017
Open	23.29
Previous Close	22.84
Day's Range	22.66 - 23.43
52-Week Range	7.33 - 23.43
Beta	0.96
Analysts	Strong Buy
Price Target	20.75 (-8.77%)
Earnings Date	Jul 31, 2025

About PARA

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,051
• Stock Exchange: NASDAQ
• Ticker Symbol: INDV
• Website: https://www.indivior.com

Analyst Summary

According to 4 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price target is $20.75, which is a decrease of -8.77% from the latest price.

Price Target

$20.75

(-8.77% downside)

Analyst Consensus: Strong Buy